☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Diabetic Neuropathy40–50 pages · PDF + Excel tracker

Diabetic Neuropathy Drug Pipeline: 10 Assets by Phase

Diabetic Neuropathy pipeline: 10 drug candidates in clinical development, 2 in Phase III, from 7 sponsors. Data as of 7 Oct 2026.

Pipeline Terminal Diabetic Neuropathy Data as of 7 Oct 2026
Candidates in development 10assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 220% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 550% of pipeline Registry
Phase I 330% of pipeline Registry
Sponsors 7top 5 hold 80% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 10526 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 4 Oct 2021.
Readouts in 12 months 3Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 3836% · Europe 23% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I3
Phase II5
Phase III2

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
SuzetriginePhase IIIJan 2027 (est.)
VX-993Phase IIMar 2027 (est.)
Experimental: Pregabalin XRPhase IIIJun 2027 (est.)

Candidates in development by lead sponsor

Zhejiang Anglikang Pharmaceutical Co., Ltd.2
Eli Lilly and Company2
Vertex Pharmaceuticals Incorporated2
Alcamena Stem Cell Therapeutics1
Novo Nordisk A/S1

Phase II and III primary completions per quarter

Q4 20260
Q1 20272
Q2 20271
Q3 20270
Q4 20270
Q1 20280
Q2 20280
Q3 20280

Answers at a glance

  • 2 of 10 diabetic neuropathy candidates (20%) are in Phase III.
  • Zhejiang Anglikang Pharmaceutical Co., Ltd. runs the largest diabetic neuropathy pipeline, with 2 candidates.
  • 3 readouts are due in 12 months; the next is Suzetrigine in Jan 2027.
  • 16 trials are recruiting patients now; 36% of all trials have a US site and 23% a European one.
10 candidates105 trials44 countriesData as of 7 Oct 2026Next refresh by 5 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 7 Oct 2026 Next refresh: by 5 Jan 2027 Change: First edition

Request a free sample

A sample of the Diabetic Neuropathy Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Diabetic Neuropathy has 10 drug candidates in active clinical development, of which 2 are in Phase III, 5 in Phase II and 3 in Phase I, according to Douglas Insights' count of 105 interventional trials registered on ClinicalTrials.gov (data as of 7 Oct 2026).

The diabetic neuropathy drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many diabetic neuropathy drugs are in each phase of development?

Douglas Insights counts 2 diabetic neuropathy candidates in Phase III, 20% of the 10 assets in development; Phase II holds 5 and Phase I holds 3.

Phase I3Phase II5Phase III2
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 7 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III220%
Phase II550%
Phase I330%
Total10100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each diabetic neuropathy asset appears in exactly one row. The 26 trials still recruiting or running carry 25% of the 105 registered trials in scope.

How many diabetic neuropathy trials are recruiting patients now?

16 diabetic neuropathy trials are recruiting patients and 6 more have not started recruiting yet, out of 105 interventional trials in scope; together they make up 21% of the trial base.

Registry statusTrialsShare
Completed5350%
Recruiting1615%
Status not verified1514%
Terminated87.6%
Not yet recruiting65.7%
Active, not recruiting43.8%
Withdrawn32.9%

Terminated, suspended and withdrawn diabetic neuropathy trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the diabetic neuropathy pipeline?

Zhejiang Anglikang Pharmaceutical Co., Ltd. leads the diabetic neuropathy pipeline with 2 candidates; the top 5 sponsors hold 80% of the 10 assets, and 7 sponsors run at least one.

SponsorAssets in developmentShare
Zhejiang Anglikang Pharmaceutical Co., Ltd.220%
Eli Lilly and Company220%
Vertex Pharmaceuticals Incorporated220%
Alcamena Stem Cell Therapeutics110%
Novo Nordisk A/S110%

Industry sponsors lead 55 of the 105 diabetic neuropathy trials (52%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the diabetic neuropathy pipeline?

Mechanism and drug-type classification for the 10 diabetic neuropathy candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What diabetic neuropathy trial readouts are coming next?

3 diabetic neuropathy candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
SuzetrigineVertex Pharmaceuticals IncorporatedPhase IIIJan 2027 (estimated)NCT06696443
VX-993Vertex Pharmaceuticals IncorporatedPhase IIMar 2027 (estimated)NCT06619860
Experimental: Pregabalin XRBrainfarma Industria Química e Farmacêutica S/APhase IIIJun 2027 (estimated)NCT07712913

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many diabetic neuropathy readouts fall in each quarter?

3 diabetic neuropathy candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 2, due in Q1 2027.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026000
Q1 2027112
Q2 2027101
Q3 2027000
Q4 2027000
Q1 2028000
Q2 2028000
Q3 2028000

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most diabetic neuropathy trials?

United States hosts the most diabetic neuropathy trials, with sites in 38 of the 105 studies (36%); trials in scope run in 44 countries in all.

CountryTrials with a siteShare of trials
United States3836%
Germany1211%
Egypt1110%
United Kingdom98.6%
Poland98.6%
Denmark98.6%
China76.7%
France65.7%

A multinational diabetic neuropathy trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are diabetic neuropathy drugs being tested?

38 of the 105 diabetic neuropathy trials (36%) have a site in the United States, 24 (23%) in Europe and 7 (6.7%) in China; 6 of the 10 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States3836%6FDA
Europe (EU/EEA, UK, Switzerland)2423%5EMA, MHRA, Swissmedic
China76.7%2NMPA
Japan32.9%2PMDA
Rest of world4139%6national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational diabetic neuropathy trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the diabetic neuropathy pipeline since the last update?

This is the first edition of the diabetic neuropathy pipeline count, dated 7 Oct 2026. The next refresh is due by 5 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the diabetic neuropathy pipeline?

Douglas Insights read 105 interventional trials registered on ClinicalTrials.gov for the conditions "Diabetic Neuropathies", "diabetic peripheral neuropathy" (excluding "diabetic foot", "diabetic foot ulcer") and updated since 4 Oct 2021, then grouped every drug or biologic named in them into 10 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Diabetic Neuropathy Pipeline Review include?

The Diabetic Neuropathy Pipeline Review covers all 10 candidates in an Excel tracker and profiles the leading 10 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 10 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where diabetic neuropathy treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every diabetic neuropathy candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in diabetic neuropathy, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Diabetic Neuropathy review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the diabetic neuropathy pipeline

How many drugs are in the diabetic neuropathy pipeline?

10 drug candidates are in active clinical development for diabetic neuropathy, with 2 in Phase III, per Douglas Insights (data as of 7 Oct 2026).

Which company has the most diabetic neuropathy drugs in development?

2 candidates make Zhejiang Anglikang Pharmaceutical Co., Ltd. the largest diabetic neuropathy pipeline sponsor, out of 7 sponsors counted by Douglas Insights.

When is the next diabetic neuropathy trial readout?

Jan 2027 is the registered primary completion of the Phase III trial of Suzetrigine (NCT06696443), the next diabetic neuropathy catalyst in Douglas Insights' calendar.

How many diabetic neuropathy trials run in the United States and Europe?

38 diabetic neuropathy trials have a US site and 24 a European site, out of 105 registered trials counted by Douglas Insights (data as of 7 Oct 2026).

How often is the diabetic neuropathy pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 7 Oct 2026 and the next is due by 5 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Diabetic Neuropathy Drug Pipeline, data as of 7 Oct 2026. https://www.douglasinsights.com/pipeline/diabetic-neuropathy/